HRP20160387T1 - Spojeni biciklični 2,4-diaminopirimidin derivat kao dualni alk i fak inhibitor - Google Patents

Spojeni biciklični 2,4-diaminopirimidin derivat kao dualni alk i fak inhibitor Download PDF

Info

Publication number
HRP20160387T1
HRP20160387T1 HRP20160387TT HRP20160387T HRP20160387T1 HR P20160387 T1 HRP20160387 T1 HR P20160387T1 HR P20160387T T HRP20160387T T HR P20160387TT HR P20160387 T HRP20160387 T HR P20160387T HR P20160387 T1 HRP20160387 T1 HR P20160387T1
Authority
HR
Croatia
Prior art keywords
degrees
alk
salt
compound
positive
Prior art date
Application number
HRP20160387TT
Other languages
English (en)
Croatian (hr)
Inventor
Martin J. Jacobs
Gregory R. Ott
Laurent Courvoisier
Shawn P. Allwein
Original Assignee
Cephalon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47892060&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20160387(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon, Inc. filed Critical Cephalon, Inc.
Publication of HRP20160387T1 publication Critical patent/HRP20160387T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
HRP20160387TT 2012-03-06 2013-03-06 Spojeni biciklični 2,4-diaminopirimidin derivat kao dualni alk i fak inhibitor HRP20160387T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261607305P 2012-03-06 2012-03-06
EP13710258.8A EP2822939B1 (en) 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
PCT/US2013/029304 WO2013134353A1 (en) 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor

Publications (1)

Publication Number Publication Date
HRP20160387T1 true HRP20160387T1 (hr) 2016-05-20

Family

ID=47892060

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160387TT HRP20160387T1 (hr) 2012-03-06 2013-03-06 Spojeni biciklični 2,4-diaminopirimidin derivat kao dualni alk i fak inhibitor

Country Status (28)

Country Link
US (5) US9132128B2 (enExample)
EP (2) EP3056494B1 (enExample)
JP (2) JP6016953B2 (enExample)
KR (1) KR102068374B1 (enExample)
CN (2) CN104159894B (enExample)
AU (1) AU2013229995B2 (enExample)
CA (1) CA2865420C (enExample)
CL (1) CL2014002353A1 (enExample)
CY (1) CY1117565T1 (enExample)
DK (1) DK2822939T3 (enExample)
EA (2) EA033124B1 (enExample)
ES (2) ES2570976T3 (enExample)
HR (1) HRP20160387T1 (enExample)
HU (1) HUE027976T2 (enExample)
IL (2) IL234239A (enExample)
ME (1) ME02460B (enExample)
MX (2) MX372740B (enExample)
MY (1) MY177290A (enExample)
NZ (1) NZ630251A (enExample)
PH (1) PH12014501979B1 (enExample)
PL (1) PL2822939T3 (enExample)
RS (1) RS54689B1 (enExample)
SG (2) SG11201405371PA (enExample)
SI (1) SI2822939T1 (enExample)
SM (1) SMT201600134B (enExample)
UA (1) UA115052C2 (enExample)
WO (1) WO2013134353A1 (enExample)
ZA (1) ZA201406147B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201405371PA (en) * 2012-03-06 2014-09-26 Cephalon Inc Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
WO2016105529A1 (en) 2014-12-23 2016-06-30 Cephalon, Inc. Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives
US12257245B2 (en) 2018-08-07 2025-03-25 In3Bio Ltd. Methods and compositions for inhibition of EGF/EGFR pathway in combination with anaplastic lymphoma kinase inhibitors
WO2024178339A2 (en) * 2023-02-23 2024-08-29 The Regents Of The University Of Michigan Methods for treating neuroblastoma with a dual anaplastic lymphoma kinase and focal adhesion kinase inhibitor
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009389A2 (en) 2003-07-23 2005-02-03 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
BR122019017579B8 (pt) 2003-08-15 2021-07-27 Novartis Ag 2,4-pirimidinadiaminas, seus usos, combinação e composição farmacêutica
DK1713806T3 (da) * 2004-02-14 2013-08-05 Irm Llc Forbindelser og sammensætninger som proteinkinaseinhibitorer
US7973061B2 (en) 2004-03-31 2011-07-05 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
JP2009528295A (ja) * 2006-02-24 2009-08-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋ経路の阻害のための組成物および方法
JP5512274B2 (ja) * 2006-10-23 2014-06-04 セファロン、インク． ＡＬＫ阻害剤およびｃ−ＭＥＴ阻害剤としての２，４−ジアミノピリミジンの縮合二環式誘導体
NZ590601A (en) * 2006-12-08 2011-09-30 Irm Llc Pyrimidine compounds especially 4-phenylamino-2-arylamino-pyrimidine derivatives and compositions as protein kinase inhibitors
BRPI0810411B8 (pt) * 2007-04-18 2021-05-25 Pfizer Prod Inc derivados de sulfonil amida para o tratamento de crescimento celular anormal, seu sos, bem como composição farmacêutica
AU2010259588B2 (en) * 2009-06-10 2015-05-28 Chugai Seiyaku Kabushiki Kaisha Tetracyclic compound
SG11201405371PA (en) * 2012-03-06 2014-09-26 Cephalon Inc Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
KR101446742B1 (ko) * 2012-08-10 2014-10-01 한국화학연구원 Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2016105529A1 (en) * 2014-12-23 2016-06-30 Cephalon, Inc. Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives

Also Published As

Publication number Publication date
JP2015509540A (ja) 2015-03-30
US9132128B2 (en) 2015-09-15
CN106166155B (zh) 2019-01-18
PH12014501979A1 (en) 2014-11-24
CA2865420A1 (en) 2013-09-12
EP2822939A1 (en) 2015-01-14
US10632119B2 (en) 2020-04-28
UA115052C2 (uk) 2017-09-11
HK1205119A1 (zh) 2015-12-11
US20150011561A1 (en) 2015-01-08
IL234239A (en) 2017-06-29
MX347772B (es) 2017-05-12
IL252364A0 (en) 2017-07-31
EP3056494A1 (en) 2016-08-17
ES2570976T3 (es) 2016-05-23
NZ630251A (en) 2016-02-26
DK2822939T3 (en) 2016-03-14
WO2013134353A8 (en) 2014-06-19
KR102068374B1 (ko) 2020-01-20
SMT201600134B (it) 2016-07-01
EP2822939B1 (en) 2016-02-17
MY177290A (en) 2020-09-10
US20150374693A1 (en) 2015-12-31
RS54689B1 (sr) 2016-08-31
EA025859B1 (ru) 2017-02-28
ZA201406147B (en) 2015-12-23
HUE027976T2 (en) 2016-11-28
SI2822939T1 (sl) 2016-04-29
CN106166155A (zh) 2016-11-30
US20170173017A1 (en) 2017-06-22
US9623026B2 (en) 2017-04-18
HK1226300A1 (zh) 2017-09-29
US9339502B2 (en) 2016-05-17
CY1117565T1 (el) 2017-04-26
EA033124B1 (ru) 2019-08-30
CN104159894B (zh) 2016-09-07
JP2017039741A (ja) 2017-02-23
AU2013229995A1 (en) 2014-09-25
JP6016953B2 (ja) 2016-10-26
AU2013229995B2 (en) 2017-04-13
US10111872B2 (en) 2018-10-30
MX2014010613A (es) 2014-09-18
SG11201405371PA (en) 2014-09-26
PL2822939T3 (pl) 2016-08-31
KR20140138247A (ko) 2014-12-03
US20190328735A1 (en) 2019-10-31
PH12014501979B1 (en) 2014-11-24
WO2013134353A1 (en) 2013-09-12
SG10201507865QA (en) 2015-10-29
EA201691574A1 (ru) 2017-03-31
US20160243119A1 (en) 2016-08-25
MX372740B (es) 2020-05-04
EA201491641A1 (ru) 2015-04-30
CL2014002353A1 (es) 2015-01-09
ME02460B (me) 2017-02-20
CN104159894A (zh) 2014-11-19
ES2681487T3 (es) 2018-09-13
EP3056494B1 (en) 2018-05-02
CA2865420C (en) 2020-06-02
IL252364B (en) 2018-03-29

Similar Documents

Publication Publication Date Title
HRP20160387T1 (hr) Spojeni biciklični 2,4-diaminopirimidin derivat kao dualni alk i fak inhibitor
HRP20201681T1 (hr) Inhibitor aurora a kinaze
HRP20190831T1 (hr) Mješavina rp/sp gemcitabin-[fenil-(benziloksi-l-alaninil)]-fosfata
BR112015023705A2 (pt) composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia)
PH12019500830A1 (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
HRP20180455T1 (hr) Natrijev (2r, 5s, 13ar) -7, 9-diokso-10- ( (2,4,6-trifluorobenzil) karbamoil) -2, 3, 4, 5, 7, 9, 13, 13a-oktahidro-2, 5-metanopirido [1’,2’ : 4.5]pirazino [2,1-b]oksazepin-8-olat
PH12015501517A1 (en) Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
BR112012027743A2 (pt) ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
HRP20210681T1 (hr) Kristalne soli (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroizokinolin-2(1h)-il)-2-hidroksipropil)pirimidin-4-karboksamida
PH12015501965A1 (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
ME02757B (me) Indoli
JP2015509540A5 (enExample)
PH12013500265A1 (en) Pharmaceutically active compounds as axl inhibitors
ME02019B (me) SPOJ IMIDAZ0[4,5-c]KINOLIN-2-0NA I NJEGOVA UPOTREBA KAO DVOJNOG INHIBITORA PI3 KINAZE I MTOR"
IL295418B1 (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
MX351305B (es) Antagonistas del receptor de mineralocorticoides.
HRP20161522T1 (hr) Derivati 6.7-dialkoksi kinazolina korisni za liječenje poremećaja povezanih s rakom
MX2016002795A (es) Compuestos de triazolona y usos de los mismos.
PH12016500322A1 (en) Amide derivatives as lysophosphatidic acid receptor antagonists
EA027986B9 (ru) Соединения триазолона и их применение
GB2488788B (en) Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
JP2013540778A5 (enExample)
MX2015008292A (es) Derivados de naftiridinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
HRP20200935T1 (hr) Farmaceutski pripravci i njihova upotreba